Ironwood Pharmaceuticals Announces It Will Expand Its Pipeline By Signing An Option Agreement To Acquire An Exclusive License With COUR Pharmaceuticals To Develop And Commercialize CNP-104 For The Treatment Of Primary Biliary Cholangitis In The U.S.

by | Nov 4, 2021 | Uncategorized | 0 comments

Meritas Media Team

Submit a Comment

Your email address will not be published. Required fields are marked *